Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
IMUGENE LIMITED (IMU)ASX AI Signals has generated 2 signal(s) for IMU during the last 90 days, indicating Moderate trading activity
Latest IMU Signals | |
| 15/05/2026 | SELL |
| 01/05/2026 | SELL |
IMU Share Price | |
| Current Price | $0.135 |
| 52 Week High | $0.445 |
| 52 Week Low: | $0.091 |
| Trading at (% of 52 Week High) | 30.34% |
Imugene Limited (ASX: IMU) is an Australian clinical-stage immuno-oncology company. It develops cancer immunotherapies aimed at activating the immune system to fight various types of cancer. The company's pipeline includes multiple therapeutic candidates focused on both solid tumors and blood cancers.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The SELL recommendation for IMUGENE LIMITED is supported by current market signals indicating potential downside risk, but the confidence is moderated by the company's sector volatility and recent price stability.
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors
LOS ALTOS, Calif. & SYDNEY, July 20, 20 Kineta, Inc.
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to i Melbourne, Victoria --News Direct-- Imugene Ltd
Imugene Ltd (ASX:IMU) CEO Leslie Chong tells Proactive that the company has dosed the first patients in cohort three of its intravenous (IV) and intratumoral (IT) monotherapy dose-escalation trial for novel cancer-killing virus VAXINIA (also known as Melbourne, Victoria --News Direct-- Imugene Ltd
Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intraveno Celularity, Inc.
Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum
Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- CeluLatest IMUGENE LIMITED(IMU) News
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial
Imugene thrilled as first patients dosed in VAXINIA MAST combination study
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial